Liu H, Dong H, Jin M, Zhou Y, Hao H, Yuan Y
Front Nutr. 2025; 12:1493792.
PMID: 39911808
PMC: 11794096.
DOI: 10.3389/fnut.2025.1493792.
Gong H, Duan S, Huang S
Front Nutr. 2025; 11():1508062.
PMID: 39834451
PMC: 11743946.
DOI: 10.3389/fnut.2024.1508062.
Hui Z, Zewu Z, Yang L, Yu C
Front Nutr. 2024; 11:1423148.
PMID: 39296511
PMC: 11408301.
DOI: 10.3389/fnut.2024.1423148.
Shimizu S
J Smooth Muscle Res. 2024; 60:23-30.
PMID: 39085088
PMC: 11291108.
DOI: 10.1540/jsmr.60.23.
Oliveira A, de Oliveira M, Monica F, Antunes E
Biomedicines. 2024; 12(5).
PMID: 38790901
PMC: 11118115.
DOI: 10.3390/biomedicines12050939.
Effects of Sleeve Gastrectomy on Pelvic Floor Disorders in Female Patients with Severe Obesity: a Prospective Study.
Gunes Y, Fersahoglu M, Esen Bulut N, Cakmak A, Ergin A, Teke E
Obes Surg. 2023; 33(10):3069-3076.
PMID: 37428362
DOI: 10.1007/s11695-023-06725-w.
Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.
Omran A, Leca B, Ostarijas E, Graham N, Da Silva A, Zair Z
Ther Adv Endocrinol Metab. 2021; 12:20420188211066210.
PMID: 34900218
PMC: 8664322.
DOI: 10.1177/20420188211066210.
Bladder Hyperactivity Induced by Oxidative Stress and Bladder Ischemia: A Review of Treatment Strategies with Antioxidants.
Wu Y, Chueh K, Chuang S, Long C, Lu J, Juan Y
Int J Mol Sci. 2021; 22(11).
PMID: 34199527
PMC: 8199707.
DOI: 10.3390/ijms22116014.
Diagnostic Potential of Low Serum Platelet, Albumin and Prolong PT-INR for Overactive Bladder and Nocturia in Chronic Hepatitis-Related Liver Cirrhosis.
Chuang P, Chang Y, Hsiao P, Chou E
J Clin Med. 2021; 10(13).
PMID: 34198972
PMC: 8268050.
DOI: 10.3390/jcm10132838.
Excessive accumulation of visceral fat is associated with lower urinary symptoms including overactive bladder in female patients.
Otsubo A, Miyata Y, Matsuo T, Mukae Y, Mitsunari K, Ohba K
Int J Urol. 2020; 28(4):397-403.
PMID: 33377223
PMC: 8048866.
DOI: 10.1111/iju.14476.
Metabolic syndrome in women with and without interstitial cystitis/bladder pain syndrome.
Peng L, Di X, He S, Zeng X, Shen H, Zhu H
Int Urogynecol J. 2020; 32(5):1299-1306.
PMID: 33215272
DOI: 10.1007/s00192-020-04605-w.
The Relationship between Overweight and Overactive Bladder Symptoms.
Hagovska M, Svihra J, Bukova A, Horbacz A, Drackova D, luptak J
Obes Facts. 2020; 13(3):297-306.
PMID: 32396899
PMC: 7445551.
DOI: 10.1159/000506486.
Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms.
Lai H, Helmuth M, Smith A, Wiseman J, Gillespie B, Kirkali Z
Urology. 2018; 123:34-43.
PMID: 30393054
PMC: 6312730.
DOI: 10.1016/j.urology.2018.09.012.
Risk factors and factors affecting the severity of overactive bladder symptoms in Korean women who use public health centers.
Chae J, Yoo E, Jeong Y, Pyeon S, Kim D
Obstet Gynecol Sci. 2018; 61(3):404-412.
PMID: 29780784
PMC: 5956125.
DOI: 10.5468/ogs.2018.61.3.404.
Epigallocatechin-3-gallate alleviates bladder overactivity in a rat model with metabolic syndrome and ovarian hormone deficiency through mitochondria apoptosis pathways.
Lee Y, Lin K, Wu B, Chuang S, Wu W, Lee Y
Sci Rep. 2018; 8(1):5358.
PMID: 29599473
PMC: 5876359.
DOI: 10.1038/s41598-018-23800-w.
Associations Between Risk Factors and Overactive Bladder: A Meta-analysis.
Zhu J, Hu X, Dong X, Li L
Female Pelvic Med Reconstr Surg. 2018; 25(3):238-246.
PMID: 29528879
PMC: 6493696.
DOI: 10.1097/SPV.0000000000000531.
Vascular risk factors for male and female urgency urinary incontinence at age 68 years from a British birth cohort study.
Tsui A, Kuh D, Cardozo L, Davis D
BJU Int. 2018; 122(1):118-125.
PMID: 29512315
PMC: 6221119.
DOI: 10.1111/bju.14137.
Schooling impacts on the overactive bladder diagnosis in women.
Ferreira L, Gameiro M, Kawano P, Yamamoto H, Guerra R, Reis L
Int Braz J Urol. 2017; 43(6):1129-1135.
PMID: 28727389
PMC: 5734077.
DOI: 10.1590/S1677-5538.IBJU.2016.0575.
Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?.
Serati M, Leone Roberti Maggiore U, Sorice P, Cantaluppi S, Agro E, Ghezzi F
Int Urogynecol J. 2016; 28(7):1033-1039.
PMID: 27942790
DOI: 10.1007/s00192-016-3219-x.
Functional and morphological alterations of the urinary bladder in type 2 diabetic FVB(db/db) mice.
Wu L, Zhang X, Xiao N, Huang Y, Kavran M, Elrashidy R
J Diabetes Complications. 2016; 30(5):778-85.
PMID: 27037041
PMC: 4912852.
DOI: 10.1016/j.jdiacomp.2016.03.003.